Bluejay director granted 100,000 options at $2.075

Q: What insider transaction did BJDX report for Donald R. Chase?

Bluejay Diagnostics (BJDX) reported a grant of 100,000 stock options to director Donald R. Chase. These options are a compensation award, not an open-market purchase or sale of Bluejay common stock.

Q: What is the exercise price of the stock options granted in the BJDX Form 4?

The granted stock options have an exercise price of $2.075 per share. They are described as out-of-the-money options and become exercisable only after vesting and FDA clearance or approval of the Symphony IL-6 device.

Q: When do Donald R. Chase’s BJDX stock options vest and expire?

The options vest on the first anniversary of the August 17, 2026 grant date. They carry an expiration date of August 17, 2031, giving a five-year term after vesting, subject to the FDA clearance condition.

Q: Are the BJDX options exercisable immediately after vesting?

No. The options are not exercisable unless and until the U.S. FDA grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device, even after the vesting date is reached.

Q: How many BJDX shares could be issued under Donald R. Chase’s new option grant?

The grant covers options on 100,000 shares of Bluejay Diagnostics common stock. Each option represents the right to buy one share at $2.075 per share if vesting and FDA clearance conditions are satisfied.

Q: Was the BJDX Form 4 transaction made under a Rule 10b5-1 trading plan?

No. The Rule 10b5-1 checkbox is not marked as affirming a trading plan. The reported transaction is a stock option grant, not an automatic sale or purchase executed under a 10b5-1 plan.

Bluejay Diagnostics, Inc. (BJDX) reported that director Donald R. Chase received a grant of 100,000 stock options to purchase common stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Bluejay Diagnostics, Inc. (BJDX) reported that director Donald R. Chase received a grant of 100,000 stock options to purchase common stock. The options have an exercise price of $2.075 per share, expire on August 17, 2031, and vest on the first anniversary of the grant date. According to the award terms, the options are not exercisable unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider CHASE DONALD R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F1	100,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 100,000 contracts (Direct)

Footnotes (1)

F1. Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.

Key Figures

Stock options granted: 100000 shares Exercise price: $2.075 per share Underlying shares: 100000 shares +2 more

5 metrics

Stock options granted 100000 shares Number of stock options granted to Donald R. Chase on August 17, 2026

Exercise price $2.075 per share Conversion or exercise price for the granted stock options

Underlying shares 100000 shares Common shares underlying the granted stock options

Options expiration date 2031-08-17 Expiration date of the granted stock options

Shares owned after transaction (options) 100000 options Total derivative securities held by Donald R. Chase following the grant

Key Terms

out-of-the-money stock options, point-of-care testing device, clearance or approval

3 terms

out-of-the-money stock options financial

"Represents out-of-the-money stock options that vest and become exercisable"

point-of-care testing device medical

"approval of the issuer's Symphony IL-6 point-of-care testing device"

clearance or approval regulatory

"shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BJDX report for Donald R. Chase?

Bluejay Diagnostics (BJDX) reported a grant of 100,000 stock options to director Donald R. Chase. These options are a compensation award, not an open-market purchase or sale of Bluejay common stock.

What is the exercise price of the stock options granted in the BJDX Form 4?

The granted stock options have an exercise price of $2.075 per share. They are described as out-of-the-money options and become exercisable only after vesting and FDA clearance or approval of the Symphony IL-6 device.

When do Donald R. Chase’s BJDX stock options vest and expire?

The options vest on the first anniversary of the August 17, 2026 grant date. They carry an expiration date of August 17, 2031, giving a five-year term after vesting, subject to the FDA clearance condition.

Are the BJDX options exercisable immediately after vesting?

No. The options are not exercisable unless and until the U.S. FDA grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device, even after the vesting date is reached.

How many BJDX shares could be issued under Donald R. Chase’s new option grant?

The grant covers options on 100,000 shares of Bluejay Diagnostics common stock. Each option represents the right to buy one share at $2.075 per share if vesting and FDA clearance conditions are satisfied.

Was the BJDX Form 4 transaction made under a Rule 10b5-1 trading plan?

No. The Rule 10b5-1 checkbox is not marked as affirming a trading plan. The reported transaction is a stock option grant, not an automatic sale or purchase executed under a 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/18/2026 - 04:16 PM Accepted by SEC EDGAR 08/18/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHASE DONALD R

(Last)

(First)

(Middle)

C/O BLUEJAY DIAGNOSTICS, INC.

360 MASSACHUSETTS AVENUE, SUITE 203

(Street)

ACTON

MASSACHUSETTS

01720

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bluejay Diagnostics, Inc. [ BJDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.075	08/17/2026		A		100,000		⁽¹⁾	08/17/2031	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.

	/s/ Donald R Chase	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR